30 closest matches · ranked by relevance
Adult Diffuse Large Cell Lymphoma · Recurrent Adult Diffuse Large Cell Lymphoma · Stage IV Adult Diffuse Large Cell Lymphoma
Primary: Objective Tumor Response — 0 participants
Marginal Zone B-cell Lymphoma
Primary: Complete Response Rate (CRR) — 73 Percentage of patients
Relapsed/Refractory Aggressive B-cell Lymphomas
Primary: Maximum Tolerated Dose (MTD) of MEDI-551 — NA; NA mg/kg
Central Nervous System Lymphoma
Primary: Complete Remission Rate After Primary Chemotherapy — 23; 30; 49 Percentage of participants
Diffuse Large B-Cell Lymphoma
Primary: Objective Response Rate (ORR) — 47.5; 46.2; 43.6 Percentage of participants — p=0.5543
Mantle Cell Lymphoma
Primary: Maximum Tolerated Dose of Lenalidomide Combined With Bortezomib and Rituximab in Phase I Participants — 10 mg lenalidomide, orally, daily, day 1-14
Lymphoma, Large Cell, Diffuse · Lymphoma, Mixed Cell, Diffuse · Primary Mediastinal Large B-Cell Lymphoma
Primary: Progression-free Survival — 72 Percent
Primary Mediastinal Large B Cell Lymphoma
Primary: Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL — 11; 1; 1; 1 Participants
Mediastinal Large B-cell Lymphoma · Richter Syndrome
Primary: Objective Response Rate (ORR) Based on International Working Group (IWG) Response Assessment Criteria Per Independent Central Review — 45.3; 13.0 Percentage of…
Non-Hodgkin Lymphoma · Mycosis Fungoides
Primary: Objective Response Rate (ORR) — 26.7; 35.7 percentage of treated subjects
Lymphoma, B-Cell
Primary: Objective Response Rate (ORR) Using International Working Group (IWG) Revised Response Criteria for Malignant Lymphoma as Assessed by Independent Central Review — 42.9…
Lymphoma, Non-Hodgkin
Primary: Progression Free Survival (PFS) — 263.1; 229.1 Weeks — p=0.3296
Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
Primary: Objective Responses in Patients With MALT Lymphoma Presenting With Measureable Disease — 25; 20; 1 Participants
Lymphoma, Mantle-Cell
Primary: Freedom From Molecular Residual Disease (MRD) Post-autologous Stem Cell Transplant (ASCT) — 41 Participants
Lymphoma, Non-Hodgkin · MALT Lymphoma
Primary: Objective Response Rate — .85 proportion of patients
Lymphoma
Primary: 2-year Progression-free Survival in Patients Treated With Rituximab-CHOP-bortezomib Induction Therapy (RCHOP-V) Followed by Bortezomib Maintenance Therapy (VM) — 62…
B-cell Lymphomas
Primary: Event-free Survival — 16 Participants
Ann Arbor Stage I Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Ann Arbor Stage II Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue · Extranodal Marginal Zone Lymphoma
Primary: Relapse-free Survival (RFS) — 83 months
Lymphoma
Primary: Progression-free Survival — 89 percentage of participants
Diffuse Large B-cell Lymphoma
Primary: 1-year Progression-free Survival — 31 Participants
CD30 Positive Primary Mediastinal Large B-cell Lymphoma · CD30-Positive Diffuse Large B-Cell Lymphoma · CD30-Positive Gray Zone Lymphoma
Primary: Number of Subjects With Dose-limiting Toxicities — 0 Participants
Lymphoma
Primary: Event-free Survival — 76 percentage of patient
Marginal Zone Lymphoma
Primary: Overall Rate of Response (ORR) in Participants Receiving Protocol Therapy. — 87.5 percentage of participants
Lymphoma, Mantle Cell · Mantle Cell Lymphoma
Primary: Progression Free Survival (PFS) — 27.2; 33.5; 7.8 Months
Diffuse Large B-cell Lymphoma
Primary: 1 Year Progression Free Survival (PFS) — 58 Percentage of participants
Lymphoma
Primary: Five-year Progression-free Survival (PFS) Rate in Patients With Newly Diagnosed Limited Stage Diffuse Large B-cell Lymphoma (DLBCL) — 87 percentage of participants
Post-transplant Lymphoproliferative Disease · Solid Organ Transplant · Stem Cell Transplant (Bone Marrow Transplant)
Primary: Overall Response Rate — 3 Participants
Diffuse Large B-cell Lymphoma
Primary: Disease-free Survival (DFS) — 77.8; 77.0 Percentage of participants — p=0.276
Relapsed or Refractory EBV-and CD30-positive Lymphomas
Primary: To Evaluate the Overall Response Rate (ORR) of Brentuximab Vedotin in EBV- and CD30-positive Lymphomas — 12 Participants
Marginal Zone B-cell Lymphoma
Primary: Overall Response Rate — 81.8 Percentage